Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

This study has been completed.
Sponsor:
Collaborator:
Arriva Pharmaceuticals, Inc.
Information provided by:
Baxalta US Inc.
ClinicalTrials.gov Identifier:
NCT00157092
First received: September 8, 2005
Last updated: June 26, 2015
Last verified: October 2006
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: October 2004
  Estimated Primary Completion Date: No date given